This commentary focuses on the cytopathology laboratory, the authors' experiences with coronavirus (COVID-19) in Taiwan, and current guidelines on COVID-19 infection prevention and control. The objective of this report is to provide cytopathology professionals a timely, in-depth, evidence-based review of biosafety practices for those at risk for coronavirus (COVID-19) infection.
